Building Better Cell Therapy Processes

20 Jan 2023
Manufacturing Advanced Therapies Track
AGC Biologics
908 Devices

11:00am Chair Introduction

Bruce Levine, Professor, Cancer Gene Therapy, University of Pennsylvania


11:05am Presentation: TBA

Lior Raviv, Chief Technical Officer, Pluri


11:20am Presentation: TBA

 Senior Representative, AGC Biologics


11:35am Presentation: TBA

Senior Representative, Triumvira Immunologics


11:50am Presentation: Benefits of Real-Time Analytics to Overcome Common Cell Culture Challenges

  • Advanced analytics are required to monitor and control critical process parameters in today’s diverse and intensified processes used in cell and gene therapies
  • We will discuss a data-driven and accelerated process optimization approach leveraging sensitive, online (sample-free) monitoring of Glucose& Lactate with automated feed control and at-line amino acid analysis

Wolfgang Künnecke, Vice President of Bioanalytics, 908Devices


12:05pm Presentation: CellPryme – Novel Enhancements for Cell Therapies

  • CellPryme-M is a method for cell manufacturing that improves in vivo persistence
  • CellPryme-A is an adjuvant approach that addresses the immunosuppressive TME
  • We have shown the synergy between the two technologies

Rebecca Lim, Senior Vice President, Scientific Affairs, Prescient Therapeutics


12:20pm Speaker Q&A

With all session participants


Bruce Levine
Barbara and Edward Netter Professor in Cancer Gene Therapy; President, International Society for Cell & Gene Therapy
University of Pennsylvania
Lior Raviv
Chief Technical Officer
Rebecca Lim
Senior Vice President - Scientific Affairs
Prescient Therapeutics
Wolfgang Künnecke
Vice President of Bioanalytics
908 Devices